-
Mashup Score: 3LEO Pharma's Tralokinumab-ldrm Autoinjector Now Available in US for Adults With Moderate to Severe Atopic Dermatitis - 2 month(s) ago
The Adbry 300 mg/2 mL autoinjector reduces the number of self injections required for patients, who currently have a 150mg/1mL pre-filled syringe available.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 3The Impact of Tropical Weather on Patients with Atopic Dermatitis in Hurricane-Prone Areas - 2 month(s) ago
Hurricane flooding results in a surge of mold, mildew, and allergens, which can trigger or exacerbate AD symptoms.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
📰 For individuals residing in hurricane-prone regions, the environmental and psychosocial challenges associated with tropical weather can exacerbate #atopicdermatitis, potentially leading to increased morbidity. #dermtwitter https://t.co/OBTi5zE1az
-
-
Mashup Score: 3Journal Digest: September 3 - 2 month(s) ago
This week’s collection of the latest dermatologic studies includes the implementation of an action plan for patients with atopic dermatitis, early childhood eczema and the risk of allergic multicomorbidities, and more.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
📚 Review our recap of the latest dermatologic studies in #atopicdermatitis, including the implementation of an action plan for patients, early childhood eczema and the risk of allergic multicomorbidities, and more. #dermtwitter https://t.co/jz2OiOf4Rg
-
-
Mashup Score: 3Defining Photosensitivity in Atopic Dermatitis - 2 month(s) ago
A recent study revealed a spectrum of photosensitivity in AD, with varying symptoms and sensitivities.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
📚 A study on #atopicdermatitis and photosensitivity reviewed 139 patients, finding varying UV sensitivities and noting that photosensitivity can evolve. #dermtwitter https://t.co/l4MUVCKdeZ
-
-
Mashup Score: 7Overcoming Therapeutic Inertia in Atopic Dermatitis—The AHEAD Recommendations as a Path Forward - 2 month(s) ago
By setting higher treatment goals, the AHEAD recommendations emphasize the importance of achieving optimal targets for both skin clearance and itch relief in atopic dermatitis.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
🌟 The recently published Aiming High in Eczema/Atopic Dermatitis recommendations provide a much-needed framework to combat therapeutic inertia in #atopicdermatitis, writes Christopher Bunick, MD, PhD. #dermtwitter https://t.co/Tw7XnNwRcs
-
-
Mashup Score: 2Action Plan Reduces AD Severity and Enhances QoL in Adults - 3 month(s) ago
The study found that after 4 weeks of using the action plan, AD severity decreased markedly, with many patients achieving mild AD status.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
📖 Researchers tested a patient action plan for adults with #atopicdermatitis and found notable improvements in disease severity, quality of life, and self-care. Over 4 weeks, AD severity, quality of life, and self-care capabilities improved. #dermtwitter https://t.co/3WgGewNywm
-
-
Mashup Score: 3New Treatment Targets for Atopic Dermatitis - 3 month(s) ago
The AHEAD recommendations focus on achieving disease control in atopic dermatitis by allowing patients to identify key symptoms and clinicians to select matching outcomes to guide therapy, aiming for a higher standard of care.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
📖 The newly-published AHEAD recommendations set new treatment goals for #atopicdermatitis based on global expert consensus. They suggest aiming for optimal targets like EASI-90 for skin clearance and itch NRS 0/1 for itch relief. #dermtwitter https://t.co/zDdJStsZWq
-
-
Mashup Score: 3Dupilumab's Ocular AEs Higher in AD Patients Than Asthma - 3 month(s) ago
The study found 95.8% of ocular AEs occurred in AD patients, while SA patients reported only 4.2% of these events.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
📚 Patients with #atopicdermatitis have a significantly higher incidence of ocular adverse events compared to patients with severe asthma. 95.8% of ocular AEs occurred in patients with AD, leading to higher treatment discontinuation rates. #dermtwitter https://t.co/Hzy3tTCS2J
-
-
Mashup Score: 4Is OX40 Inhibition the Next Game Changer for Atopic Dermatitis? - 3 month(s) ago
Learn more about the OX40-OX40L pathway and 2 drugs heading toward phase 3 trials.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
🌟📰 Within the past 5 years, it has been exciting to see new treatments cater to targeting fundamental pathways in #atopicdermatitis. Recent research has looked into the OX40-OX40L pathway. #dermtwitter https://t.co/sHY5unnJ9D
-
-
Mashup Score: 2
Explore how surveyed providers perceive current and emerging therapies in the atopic dermatitis.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet-
🌟 The latest data from Spherix Global Insights provided a look at how providers perceive current and emerging therapies in the #atopicdermatitis market, particularly focusing on awareness and opinions of lebrikizumab and nemolizumab. #dermtwitter https://t.co/cLD3WKf5ka
-
❗️LEO Pharma's 300 mg/2 mL single-dose autoinjector of tralokinumab-ldrm (Adbry) is now available for US adults with moderate to severe #atopicdermatitis. #dermtwitter https://t.co/rD3vdyQmYZ